Cardiac troponins: outcome predictors in hemodialysis patients

Abstract

Cardiovascular diseases represent the main cause of death in hemodialysis (HD) patients. Cardiac troponins (cTnT and cTnI) are indicators of myocardial damage. The aims of this study were to assess the prevalence of increased serum cTn in the absence of acute coronary syndrome, to determine overall and cardiovascular mortality rates, and to investigate the possible predictive values of cTnT and cTnI on the outcome in HD patients over a 2-year follow-up period. The study included 115 patients (71 men and 44 women) with an average age of 53.30 +/- 12.17 years who had undergone regular HD for 4.51 +/- 4.01 years and had a mean HD adequacy (Kt/Vsp) of 1.17 +/- 0.23. Increased serum cTnT concentration was found in 37.39% of patients and elevated serum cTnI concentration was present in 11.30% of HD patients without symptoms or signs of acute coronary syndrome. The average 2-year mortality rate was 13.74% and the average 2-year cardiovascular mortality rate was 8.51%. Patients with serum cTnT levels greater than 0.10 ng/ml had significantly lower overall and cardiovascular survival rates than patients with serum cTnT levels of less than 0.10 ng/ml. Patients with serum cTnI levels greater than 0.15 ng/ml had significantly lower overall and cardiovascular survival rates than patients with serum cTnI of less than 0.15 ng/ml. In patients on regular HD, cTn levels are significant outcome predictors.